Skip to main content
. 2022 May 30;29(6):3911–3921. doi: 10.3390/curroncol29060312

Figure 2.

Figure 2

(A) Progression-free survival and (B) cancer-specific survival of 99 patients with upper tract urothelial carcinoma stratified using expression of trophoblast cell surface antigen 2 (Trop-2, 0/1+/2+ vs. 3+).